Gilead (NASDAQ: GILD) CFO sells 3,000 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson reported a small, pre-planned stock sale. On January 15, 2026, he sold 3,000 shares of Gilead common stock at a price of $124.31 per share. After this transaction, he continued to beneficially own 150,503 shares of the company’s common stock in direct ownership.
The sale was executed under a Rule 10b5-1 trading plan that was adopted on August 29, 2024, meaning the trade was scheduled in advance under a preset plan rather than being decided at the time of sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 3,000 shares ($372,930)
Net Sell
1 txn
Insider
Dickinson Andrew D
Role
Chief Financial Officer
Sold
3,000 shs ($373K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,000 | $124.31 | $373K |
Holdings After Transaction:
Common Stock — 150,503 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Gilead Sciences (GILD) report for its CFO?
Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson reported the sale of 3,000 shares of Gilead common stock on January 15, 2026.
What type of filing reported the Gilead (GILD) CFO stock sale?
The transaction was disclosed in a Form 4, which reports changes in the beneficial ownership of a company’s equity securities by insiders.